ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease

05 Apr 2025 11:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference

31 Mar 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference

24 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update

12 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025

05 Feb 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio

27 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease

15 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

13 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

06 Jan 2025 07:30:00 By Nasdaq GlobeNewswire

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

26 Dec 2024 12:00:28 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

24 Dec 2024 09:45:04 By NetDania Notify

NetDania - New 12 months High: ANAVEX LIFE SCIENCES CORP. - COMMON STOCK

23 Dec 2024 09:57:16 By NetDania Notify

Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update

23 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease

23 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024

16 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference

09 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024

02 Dec 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA

26 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal

25 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

31 Oct 2024 04:00:00 By Nasdaq GlobeNewswire